Drug profile

The FDA adverse-event record for Glucosamine Hydrochloride

Name: Glucosamine Hydrochloride - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Hydrochloride. See the species affected, top reactions, and outcomes below.

11
adverse-event reports: 0.0%
death-coded share: Dog
most-reported species: 2
Lack of efficacy - NOS - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

0.0%

Death Rate

Active Ingredients

Glucosamine Hydrochloride

Administration Routes

UnknownOral

Species Affected

Dog 11

Most Affected Breeds

Boxer (German Boxer) 2

Retriever - Labrador 2

Shar Pei 2

Pointing Dog - Hungarian Short-haired (Vizsla) 1

Ridgeback - Rhodesian 1

Shepherd Dog - German 1

Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Siberian Husky 1

Most Reported Reactions

Lack of efficacy - NOS 2

Decreased appetite 2

Arthritis 2

Vomiting 2

Elevated alanine aminotransferase (ALT) 2

Local swelling (not application site) 2

Difficulty going up/down stairs 2

Lying down 2

Joint ligament disorder NOS 2

Drinking a lot 1

Lethargy (see also Central nervous system depression in 'Neurological') 1

Emesis 1

Outcome Breakdown

Ongoing

5 (45.5%)

Outcome Unknown

3 (27.3%)

Recovered/Normal

3 (27.3%)

Glucosamine Hydrochloride Adverse Event Insights

11 reports name Glucosamine Hydrochloride; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Hydrochloride. Administration routes: Unknown, Oral.

By species: Dog (11 reports). By breed: Boxer (German Boxer) (2), Retriever - Labrador (2), Shar Pei (2).

Leading clinical signs: Lack of efficacy - NOS (2), Decreased appetite (2), Arthritis (2), Vomiting (2). Outcome, 11 coded reports: Ongoing leads at 45.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.